```

[Federal Register Volume 89, Number 239 (Thursday, December 12, 2024)]
[Notices]
[Pages 100508-100509]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-29237]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-D-1716]

Registration and Listing of Cosmetic Product Facilities and 
Products; Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is 
announcing the availability of a final guidance for industry entitled 
``Registration and Listing of Cosmetic Product Facilities and 
Products.'' The guidance will assist persons submitting cosmetic 
product facility registrations and product listing submissions to FDA 
under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). 
This guidance includes three new draft frequently asked questions and 
answers about cosmetic product facility registrations and product 
listing submissions, in Appendix B, for comment purposes only. Aside 
from the three new draft frequently asked questions and answers, this 
guidance finalizes the draft Appendix B published in an otherwise final 
guidance on December 19, 2023. This guidance also includes minor 
changes to the final guidance for clarity.

DATES: The announcement of the guidance is published in the Federal 
Register on December 12, 2024. However, the portion of this guidance in 
Appendix B that describes three new frequently asked questions and 
answers, is being distributed for comment purposes only. To ensure that 
the Agency considers your comment on this draft section before it 
begins work on the final version of this section of the guidance, 
submit either electronic or written comments on this section by January 
13, 2025.

ADDRESSES: You may submit either electronic or written comments on 
Agency guidances at any time as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2023-D-1716 for ``Registration and Listing of Cosmetic Product 
Facilities and Products.'' Received comments will be placed in the 
docket and, except for those submitted as ``Confidential Submissions,'' 
publicly viewable at https://www.regulations.gov or at the Dockets 
Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-
402-7500.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states

[[Page 100509]]

``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, 240-402-7500.
    You may submit comments on any guidance at any time (see 21 CFR 
10.115(g)(5)).
    Submit written requests for single copies of the guidance to Office 
of the Chief Scientist, Office of the Commissioner, Food and Drug 
Administration, 10903 New Hampshire Ave., WO1, Silver Spring, MD 20993-
0002. Send two self-addressed adhesive labels to assist that office in 
processing your request. See the SUPPLEMENTARY INFORMATION section for 
electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT: Jennifer Ross, Office of the Chief 
Scientist, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 1, Rm. 4332, Silver Spring, MD 20993-0002, 301-796-4880 (this is 
not a toll-free number).

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a guidance for industry 
entitled ``Registration and Listing of Cosmetic Product Facilities and 
Products.''
    On December 29, 2022, the President signed the Consolidated 
Appropriations Act, 2023 (Pub. L. 117-328) into law, which included 
MoCRA. Among other provisions, MoCRA added section 607 to the Federal 
Food, Drug, and Cosmetic Act (FD&C Act), establishing requirements for 
cosmetic product facility registration and cosmetic product listing. 
Section 607(a) of the FD&C Act (21 U.S.C. 364c(a)) requires every 
person that owns or operates a facility that engages in the 
manufacturing or processing of a cosmetic product for distribution in 
the United States to register each facility. In addition to the 
registration requirements, section 607(c) of the FD&C Act requires that 
for each cosmetic product, the responsible person submit to FDA ``a 
cosmetic product listing.'' Certain small businesses, as defined in 
section 612 of the FD&C Act (21 U.S.C. 364h), are exempt from the 
registration and listing requirements.
    In the Federal Register of December 19, 2023 (88 FR 87780), we made 
available a final guidance for industry entitled ``Registration and 
Listing of Cosmetic Product Facilities and Products.'' This guidance 
also included a new draft section, Appendix B, for comment purposes 
only, that describes frequently asked questions and answers about 
cosmetic product facility registrations and product listing submissions 
and gave interested parties an opportunity to submit comments by 
January 18, 2024, for us to consider before beginning work on the final 
version of Appendix B. We received a few comments on the draft guidance 
Appendix B frequently asked questions and answers and have modified the 
final guidance Appendix B in response to these comments and for 
clarity, where appropriate. In addition, we made editorial changes to 
the final guidance to improve clarity. Finally, three new frequently 
asked questions and answers in Appendix B of this guidance are 
highlighted in grey and are marked ``for comment purposes only'' to 
provide an opportunity for comment before they are finalized. Aside 
from the three new frequently asked questions and answers in Appendix 
B, this guidance finalizes the draft guidance Appendix B that was 
published on December 19, 2023 (88 FR 87780) and reissues the final 
guidance with minor changes for clarity. No changes were made to 
Appendix A of the final guidance.
    This guidance is being issued consistent with FDA's good guidance 
practices regulation (21 CFR 10.115). The guidance represents the 
current thinking of FDA on ``Registration and Listing of Cosmetic 
Product Facilities and Products.'' It does not establish any rights for 
any person and is not binding on FDA or the public. You can use an 
alternative approach if it satisfies the requirements of the applicable 
statutes and regulations.

II. Paperwork Reduction Act of 1995

    While this guidance contains no collection of information, it does 
refer to previously approved FDA collections of information. The 
previously approved collections of information are subject to review by 
the Office of Management and Budget (OMB) under the Paperwork Reduction 
Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information 
in section 607 of the FD&C Act have been approved under 0910-0599.

III. Electronic Access

    Persons with access to the internet may obtain the guidance at 
https://www.fda.gov/CosmeticGuidances, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.

    Dated: December 5, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2024-29237 Filed 12-11-24; 8:45 am]
BILLING CODE 4164-01-P
```